Disc Medicine Shares FDA Meeting Outcomes for Bitopertin
WATERTOWN, Massachusetts, June 9, 2026 Disc Medicine announced a regulatory update following a Type A meeting with the U.S....
Phase 3 Study
Advertisement
Neurocrine Biosciences Reports New INGREZZA Data in Tardive Dyskinesia
SAN DIEGO, June 8, 2026 Neurocrine Biosciences announced new clinical findings demonstrating the long-term effectiveness of INGREZZA® (valbenazine) capsules...
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
AstraZeneca’s Imfinzi Wins FDA Approval in NMIBC
CAMBRIDGE, United Kingdom, May 28, 2026 AstraZeneca has achieved a significant milestone in bladder cancer treatment with the U.S....
Junshi Biosciences Phase 3 Trial Confirms JS001sc Success in NSCLC
SHANGHAI, China, Nov. 25, 2025 — Junshi Biosciences announced that its Phase 3 clinical study evaluating JS001sc, a subcutaneous...
Advertisements
Merck Reports Positive HYPERION Results for Pulmonary Hypertension Therapy
RAHWAY, N.J., Sept. 30, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...
Advertisement
